Generic Medicine Info
May be taken with or without food. Take consistently either always w/ or always w/o meals.
Undiagnosed abnormal genital bleeding, androgen-dependent tumour, thromboembolic disease or history of thrombosis, severe cardiac impairment. Severe hepatic and renal impairment. Pregnancy and lactation.
Special Precautions
Patient w/ epilepsy, migraine, DM, polycythaemia, HTN and other CV disease, porphyria, lipoprotein disorder. Hepatic or renal impairment. Monitoring Parameters Perform LFT and renal function test periodically. Monitor haematologic parameters, lipid panel, signs and symptoms of intracranial HTN, androgenic changes, and/or fluid retention.
Adverse Reactions
Significant: Androgenic effects (e.g. acne, seborrhoea, wt gain, hair loss, voice change, clitoral hyperthrophy), peliosis hepatis, benign hepatic adenoma, cholestatic jaundice, benign intracranial HTN. Nervous: Nervousness, emotional lability, headache. CV: Palpitations, tachycardia. Resp: Interstitial pneumonitis. Genitourinary: Vaginal dryness and irritation; abnormal semen volume, sperm count, viscosity and motility. Endocrine: Menstrual disturbances. Dermatologic: Rash, Steven-Johnsons syndrome, erythema multiforme.
Potentially Fatal: Thromboembolism, thrombotic and thrombophlebitic events, including sagittal sinus thrombosis and stroke.
Drug Interactions
May prolong prothrombin time when used w/ warfarin. May increase serum concentrations of carbamazepine, ciclosporin, tacrolimus. Increased risk of myopathy and rhabdomyolysis when concurrently administered w/ statins (e.g. simvastatin, atorvastatin, lovastatin). May increase calcaemic response to synthetic vit D analogs. May cause insulin resistance.
ATC Classification
G03XA01 - danazol ; Belongs to the class of antigonadotropins and similar agents.
Disclaimer: This information is independently developed by CIMS based on danazol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in